Is US Preparing For A Quademic 2025?

Updated Jan 15, 2025 | 03:10 PM IST

SummaryQuademic 2025: It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.
Is US preparing for a quademic?

Credits: Canva

Quademic 2025: Hospitals in the United States are dealing with a surge in patients admission, the reason is the quademic it is dealing with at this moment. This has led to an influx of patients. It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.

The healthcare company founded in academics M Health Fairview, confirmed that their hospitals are overflowing due to the quademic.

Is US able to cope with Quademic 2025?

The hospitals of M Health Fairview's volume is up by 30% and as a results, patients are being treated in the hallways and in alternative care areas. There is also a longer wait time and shortages for resources that are required to treat these emergencies. This has also impacted other life-threatening emergencies like heart attacks and strokes, as the healthcare resources and caregivers are occupied with the surge in seasonal cases.

ALSO READ: Birmingham Struggles With 4 Different Virus Hits, Know What They Are

What are these quademic infections?

Common cold and flu: The common cold and influenza (flu) are perhaps the most well-known illnesses that peak during the fall. As temperatures drop and humidity levels fluctuate, viruses that cause colds and the flu become more active. The flu, in particular, can be more severe than a common cold, leading to complications such as pneumonia, especially in vulnerable populations like the elderly and those with pre-existing health conditions. Symptoms include a runny nose, sore throat, coughing, fever, and body aches.

Covid-19: As per the World Health Organization, Coronavirus disease or COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment, However, there could be some cases of seriously ill patients who may require medical attention. It is also because of the other existing medical conditions like cardiovascular diseases, diabetes, chronic respiratory diseases, cancers, or older age.

The best way to protect against this virus is by following social isolation form those who are infected, using mask to prevent droplets from infecting others when you cough or sneeze and to wash your hands for 20 seconds frequently.

RSV or Respiratory Syncytial Virus: As per the Centers of Diseases Control and Prevention (CDC), RSV is a common respiratory virus that infects nose, throat and lungs. Though symptoms are similar to the viruses like flu or COVID-19, the disease in itself is different. It also peaks during the winter season, especially between December and January.

However, the main difference between RSV and other respiratory illness, above mentioned is that RSV can cause pneumonia or bronchiolitis, especially for those who are over the age of 50 or with an existing heart or lung disease.

Norovirus: It is a number 1 cause of foodborne illness in the US and this happens when virus gets into the food and then it accidentally enters your mouth. These particles are from faeces or vomit from infected people, or can be transmitted via contaminated food and water. It could also spread by touching unclean surfaces like door handles or cutlery.

For most people, having norovirus is unpleasant, but mild and recovery could be made in 1 to 2 days. However, it could be more serious for babies, older people and anyone with any existing health condition.

End of Article

India Proposes Tighter Antimicrobial Drug Regulation To Combat AMR: What It Means

Updated Nov 19, 2026 | 12:27 PM IST

SummaryThe proposed draft would require antimicrobial manufacturers to obtain central approval before seeking state manufacturing licences. The Ministry has also proposed separate licences for the wholesale sale of bulk drugs.
India Proposes Tighter Antimicrobial Drug Regulation To Combat AMR: What It Means

Credit: iStock

Amid rising antimicrobial resistance (AMR) worldwide, the Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under central regulatory oversight.

The amendment seeks to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v). Manufacturers would need central approval before applying for a manufacturing licence from state authorities.

"The proposal is intended to serve as an additional regulatory safeguard against antimicrobial resistance (AMR) by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before the grant of new manufacturing licences," the Ministry said.

AMR occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat infections. This makes infections harder to treat, increases the risk of severe illness and death, and can complicate medical procedures such as surgery and cancer treatment.

Addressing the World Antimicrobial Resistance (AMR) Awareness Week 2026, Union Health Secretary Punya Salila Srivastava described AMR as one of the most serious public health challenges. She warned that misuse and overuse of antimicrobials could make even common infections difficult to treat and threaten decades of medical progress.

Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

What Does The Proposed Amendment Say?

The Ministry proposed the amendment through draft Gazette Notification G.S.R. 983 (E), dated November 6.

Manufacturers would need permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA).

Existing manufacturing licences will remain valid, and holders will not need to reapply for permission.

The measure is expected to strengthen central oversight and help ensure the quality, safety and efficacy of antimicrobial products, the Ministry said.

Why Does India Want To Tighten Antimicrobial Regulation?

Read More: ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

The proposal follows concerns that antimicrobial manufacturing licences are being granted without adequate regulatory scrutiny, including bioavailability/bioequivalence (BA/BE) and stability studies.

The absence of these assessments may affect product quality, safety and efficacy. Substandard or ineffective antimicrobials can contribute to AMR and pose risks to patient safety.

"The measure is part of the Government's broader efforts to promote the responsible use of antimicrobials, safeguard patient safety and address the growing public health challenge of AMR," the Ministry said.

The amendment remains at the draft stage. The Ministry has invited objections and suggestions from stakeholders and the public before finalisation.

Separate Licences For Bulk Drug Sales

In addition, the Ministry has proposed amendments to the Drugs Rules, 1945, to introduce separate application and licence forms for the wholesale sale of bulk drugs, including active and inactive bulk substances.

Currently, a common licence covers the wholesale sale of both formulations and bulk drugs.

The proposed framework would allow more focused oversight of bulk drug sales and improve accountability in the pharmaceutical supply chain, the Ministry said.

Licences would specify the categories of bulk drugs handled by wholesalers, including those covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Bulk drug sales would also require the personal supervision of a competent person.

End of Article

Flu Activity Rises Across Americas As Northern Hemisphere Enters Winter 2026; WHO Issues Alert

Updated Nov 19, 2026 | 11:08 AM IST

Summary Influenza positivity in the US increased to 9.1%, while Canada reported 10.8% as H1N1 emerged as the predominant flu subtype in both countries. The WHO has urged stronger surveillance and vaccination against influenza and RSV.
Flu Activity Rises Across Americas As Northern Hemisphere Enters Winter 2026; WHO Issues Alert

Credit: iStock

The United States and other countries in the Americas are witnessing increasing influenza activity as the Northern Hemisphere enters the 2026–27 respiratory virus season.

In a November 17 epidemiological alert, the Pan American Health Organization (PAHO) and World Health Organization (WHO) urged countries to strengthen surveillance of respiratory viruses, prepare healthcare services for a possible increase in demand and accelerate seasonal influenza and respiratory syncytial virus (RSV) vaccination among priority groups before the peak of viral circulation.

US Sees Increase In Flu, RSV And Other Respiratory Viruses

The report noted that influenza, RSV and other respiratory viruses have gradually increased in the US. Overall respiratory virus activity is higher than typically observed at this time of year.

Influenza positivity increased from 7.6% in the week ending October 18 to 9.1% in the week ending October 25. Influenza A(H1N1)pdm09 emerged as the predominant subtype.

Influenza-like illness (ILI) activity was classified as high in two states, Louisiana and South Carolina. Hospital surveillance data also showed a gradual increase in influenza-associated hospitalisation rates.

Also read: US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Canada Reports Earlier Flu Season, Rising COVID-19 Activity

Canada is also witnessing an increase in influenza circulation, which began earlier than in previous post-pandemic seasons between 2022–23 and 2025–26.

Influenza positivity reached 10.8% in the week ending October 25, with activity shifting from low to moderate levels. Unlike the previous season, influenza A(H1N1)pdm09 is the predominant subtype.

COVID-19 circulation is also gradually increasing in Canada but remains low and below levels observed in previous seasons. SARS-CoV-2 positivity stood at 5.8%.

Hospitalisations associated with respiratory viruses are also rising, reaching 2.6 per 100,000 population. Influenza-associated hospitalisations reached 1.2 per 100,000, while the rate for COVID-19-associated hospitalisations was 1.3 per 100,000. However, PAHO/WHO noted that these rates remain low and within the expected range for this time of the season.

Influenza Activity Increases Across Northern Hemisphere

Read More: G155E H1N1 Mutation In US Raises Concerns: Can This Year’s Flu Shot Still Protect You?

Globally, influenza activity is following expected seasonal patterns, with a gradual increase over recent months in temperate and subtropical regions of the Northern Hemisphere. Influenza positivity in these regions is approaching 10%.

Some countries in North America, Central America and the Caribbean, as well as in Africa, Asia and Europe, have reported influenza positivity rates above 10%, according to the alert.

In contrast, influenza activity has declined over the past two months in temperate and subtropical regions of the Southern Hemisphere, where positivity has fallen to around 5%.

RSV Circulation Remains High In Some Countries

READ: Flu 2026: Symptoms To Watch For As New Season Begins

Alongside increasing influenza activity, PAHO/WHO highlighted high RSV circulation in some countries in the Northern Hemisphere.

Globally, RSV positivity rates above 10% were observed in some countries, particularly in tropical and subtropical regions.

The organization warned that the circulation of multiple respiratory viruses makes it important for countries to strengthen healthcare preparedness ahead of seasonal peaks.

Strengthen Surveillance, Boost Vaccine Uptake

PAHO/WHO has called on member states to strengthen integrated epidemiological and virological surveillance of respiratory viruses, including timely genomic characterization to monitor viral evolution.

It has also recommended that countries adjust healthcare preparedness and organizational plans in anticipation of a possible increase in demand for medical services.

The alert also urges countries to accelerate seasonal influenza and RSV vaccination among priority groups, in line with current recommendations and before periods of increased viral circulation.

End of Article

Canada Approves Daily GLP-1 Pill As New Study Finds Drugs May Outperform Metformin In Diabetes Management

Updated Nov 19, 2026 | 09:11 AM IST

SummaryEli Lilly's GLP-1 pill Foundayo will be available for purchase in Canada from January 2027. Health Canada's approval comes just as a recent study observed GLP-1 drugs beat metformin in diabetes prevention.
Canada Approves Daily GLP-1 Pill As New Study Finds Drugs May Outperform Metformin In Diabetes Management

Credit: AI

Canada's regulatory body Health Canada recently approved GLP-1 pill developed by pharmaceutical company Eli Lilly. The weight loss pill offers an alternative to injectable weight-loss and diabetes medications.

The development comes as new study suggests that GLP-1 drugs could be more effective than metformin in preventing Type 2 diabetes and improving blood sugar in people with obesity and prediabetes.

The newly approved drug, Foundayo (orforglipron) is approved for adults with obesity and have at least one related health condition. It is also approved to help manage Type 2 diabetes.

Unlike popular GLP-1 medications like Ozempic and Wegovy, which are administered through injections, Foundayo is taken orally once a day. The company expects the GLP-1 pill to become available in Canadian pharmacies in January 2027.

How Does Foundayo Work?

Also read: Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1 (GLP-1), which is naturally-occurring hormone released by the gut after eating.

GLP-1 helps regulate blood sugar by stimulating insulin release when glucose levels increase. It also suppresses glucagon, a hormone that raises blood sugar, slows emptying of stomach and targets areas of the brain responsible for appetite. These effects, together, help improve blood sugar control, reduce hunger and support weight loss.

Unlike peptide-based GLP-1 medicines, orforglipron is a small molecule that can be absorbed orally without being broken down by digestive enzymes. It can also be taken without the food and water restrictions that come with some oral GLP-1 medications.

Novo Nordisk’s Rybelsus is already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.

Can GLP-1 Drugs Outperform Metformin?

Also read: New Chinese Weight-Loss Injection Ribupatide Shows Over 17% Weight Loss In 48 Weeks: Could It Rival Mounjaro?

A separate study presented at the American Heart Association's Scientific Sessions 2026 compared GLP-1 medications to metformin in more than 256,000 adults with obesity and prediabetes.

Researchers found that people taking GLP-1 medications were 1.5 times more likely to return to normal blood sugar levels than those taking metformin. They also had a 31% lower risk of developing Type 2 diabetes and a 41% lower risk of death from any cause. GLP-1 users were also at lower risks of heart attacks, strokes and heart failure events.

But the study analysed health records rather than conducting a randomised clinical trial. It also grouped several GLP-1 medicines together, including semaglutide, tirzepatide, liraglutide and dulaglutide. Orforglipron was not among the drugs evaluated.

Study author Vinicius de Sousa Barzon Serra said, "Metformin is still a first-line treatment choice. It is safe, inexpensive and has a long track record. This is less about replacing one medication with another and more about discussing additional options with specific patients."

Side Effects Of GLP-1 Medications

Common side effects of GLP-1 medications include gastrointestinal effects like nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These symptoms are often more noticeable when treatment begins or doses increase.

Although oral medicines offer an alternative to injections, they are not suitable for everyone. It depend on a person's medical history, blood sugar levels, weight and other health conditions.

End of Article